Chocolate From Wegmans Grocery Stores Recalled
On Monday, the Food and Drug Administration (FDA) announced that Mellace Family Brands California, Inc. of Warren, OH has recalled Wegmans Semi – Sweet Chocolate Nonpareils from shelves over an undeclared milk allergen.
No illnesses have been reported to date, but the recall was initiated after it was discovered the nonpareils were sold in packages that did not mention the presence of milk. Reportedly, the packaging omission was due to "a temporary breakdown in the suppliers' manufacturing process."
"People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product with the lot codes shown below," said the FDA announcement.
The product is sold in 18.5 oz. plastic tubs with the UPC code 0 77890 49787 6. The affected lot codes are as follows:
55021 BEST BY: DEC 28, 2025
55031 BEST BY: DEC 29, 2025
55491 BEST BY: FEB 13, 2026
55501 BEST BY: FEB 14, 2026
56061 BEST BY: APR 11, 2026
56071 BEST BY: APR 12, 2026
The affected chocolates were sold in grocery stores in eight states--Delaware, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania and Virginia--as well as Washington, D.C.
Anyone who bought one of the affected packages is asked to return it to the place of purchase for a refund.
Meanwhile, customers can reach Wegmans Food Markets at 1-855-934-3663 daily from 8 a.m. to 8 p.m. ET.
Chocolate From Wegmans Grocery Stores Recalled first appeared on Men's Journal on Jul 1, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
Young kids, babies are getting into nicotine pouches. What parents should know.
Poison control centers are sounding the alarm on nicotine pouches as cases of young children accidentally ingesting them surge around the country. The warning comes amid new research showing calls that involved children under 6 increased by 763% from 2020 to 2023, according to the study published July 14 in the journal Pediatrics. The steep increase in calls to poison control centers is partly due to the rising popularity of nicotine pouches, said Natalie Rine, study co-author and director of the Central Ohio Poison Center. Children were also home more during this period as the pandemic prompted stay-at-home orders, which gave them more access to nicotine products stored in the house. 'The popularity of these products started in 2019,' she said. 'There was a large increase in sales between 2019 and 2022… and we started getting calls more frequently.' Nicotine pouches, sometimes referred to as "lip pillow" or "upper decker," are small microfiber pouches containing nicotine powder. Here's what parents should know about keeping their kids safe from nicotine pouches. 'Nicotine hiccups': What are they and why do they happen? How is nicotine dangerous to kids? Nicotine pouches were 1.5 times more likely to be associated with a serious medical outcome and twice as likely to be associated with a medical admission compared to any other nicotine product included in the study, such as cigarettes or liquid nicotine. Nicotine is a highly toxic substance to young children, especially in a concentrated form like a nicotine pouch, according to Nationwide Children's Hospital in Columbus, Ohio. FDA seeks to limit nicotine in cigarettes, most cigars. Vapes and Zyn are excluded. After ingestion, some minor symptoms can include nausea and vomiting, Rine said. But as the dose increases, children can experience high blood pressure and a fast heart rate, which can escalate to seizures and respiratory failure. Among the 135,000 calls made to poison control centers between 2010 and 2023, study authors found that nicotine was linked to two deaths in children under 6. How to prevent an emergency The best way to prevent a child from ingesting a nicotine pouch is to keep products out of the house, Rine said. If parents or guardians choose to keep nicotine products at home, she recommends they take the following precautions: What to do if your kid swallows a nicotine pouch If a child is experiencing a medical emergency, Rine urges parents to call 911. If they're showing mild symptoms, she recommends calling the national Poison Help Line to access free, confidential expert advice from specially trained nurses and pharmacists. 'We're always there to help talk you through what symptoms you're seeing with the child, based on the history that's given,' Rine said. She warns against trying to induce vomiting, as that can lead to a secondary problem if fluid enters the lungs. 'Inducing vomiting is one of the bigger misconceptions that's out there,' Rine said. 'More often than not, you have the potential to cause more of a problem than what you're already dealing with.' Adrianna Rodriguez can be reached at adrodriguez@
Medscape
an hour ago
- Medscape
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a supplemental new drug application for brexpiprazole (Rexulti, Otsuka Pharmaceutical Co., Ltd.), in combination with sertraline, for the treatment of adults with posttraumatic stress disorder (PTSD). If approved, it would be the first new treatment for PTSD in more than 20 years. 'It is my hope that the FDA does approve this treatment for two related reasons — the data look positive and compelling, and there's a tremendous unmet need in PTSD,' Roger McIntyre, MD, professor of psychiatry and pharmacology and head of the Mood Disorders Psychopharmacology Unit, University of Toronto, Toronto, Ontario, Canada, told Medscape Medical News. What's in the Treatment Toolbox Now? PTSD is a 'common, severe, and nonremitting condition,' McIntyre noted. According to the National Center for PTSD, the condition affects roughly 13 million adults in the US in any given year. This represents about 5% of the adult population. PTSD can develop following exposure to traumatic events such as combat, assault, disasters, or severe accidents. Core symptoms of PTSD include intrusive memories and flashbacks, avoidance behaviors, negative alterations in mood and cognition, and hyperarousal. Currently, the selective serotonin reuptake inhibitors (SSRI), sertraline and paroxetine, are the only FDA-approved medications for PTSD, and while these medications can be effective, many patients fail to achieve remission or discontinue treatment due to side effects or lack of response. Other medications used off-label to treat PTSD — including prazosin, mirtazapine, atypical antipsychotics, and mood stabilizers — have shown variable efficacy. There has not been a new FDA-approved drug for PTSD in over two decades, underscoring the need for better therapeutic options, particularly for patients who do not fully respond to SSRI alone. Why Brexpiprazole Plus Sertraline? Brexpiprazole is an atypical antipsychotic currently approved as adjunctive treatment of major depressive disorder (MDD) in adults; treatment of schizophrenia in adults and adolescents aged 13 years or older; and treatment of agitation associated with Alzheimer's dementia. The combination of brexpiprazole and sertraline could address the limitations of SSRI alone by working synergistically to treat PTSD. Sertraline increases serotonin levels in the brain to improve mood and reduce anxiety. Brexpiprazole has a complex mechanism of action involving multiple neurotransmitter systems, including but not limited to serotonin and dopamine. Together, they may target different aspects of PTSD, potentially leading to a more comprehensive reduction in symptoms. What Do the Phase 3 Data Show? In a pivotal, double-blind, randomized controlled, phase 3 trial, brexpiprazole plus sertraline provided significantly greater relief of PTSD symptoms than sertraline plus placebo. The results were published late last year in JAMA Psychiatry and reported by Medscape Medical News at that time. The trial enrolled 416 adults (mean age, 37 years; 75% women) aged 18-65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-5 ) diagnosis of PTSD and symptoms for at least 6 months prior to screening. At baseline, participants had a mean Clinician Administered PTSD Scale (CAPS-5) for DSM-5 total score of 38.4, indicating moderate to high severity PTSD. The average time from the index traumatic event was 4 years, and three fourths had no prior exposure to PTSD prescription medications. Participants underwent a 1-week placebo run-in period followed by randomization to daily oral brexpiprazole 2-3 mg plus sertraline 150 mg or daily sertraline 150 mg plus placebo for 11 weeks. At week 10, brexpiprazole plus sertraline demonstrated statistically significant greater improvement in the CAPS-5 total score (primary outcome) than sertraline plus placebo (mean change, -19.2 points vs -13.6 points; P < .001). Brexpiprazole plus sertraline also led to statistically significant greater improvement on all key secondary and other efficacy endpoints, both clinician-reported and patient-reported, including measures of anxiety, depression, intrusive symptoms, hyperarousal, and overall functioning. Combining an atypical antipsychotic with an antidepressant for PTSD 'builds on what we've been doing in depression,' Elspeth Ritchie, MD, chair of Psychiatry, MedStar Washington Hospital Center, Washington, DC, noted in an interview with Medscape Medical News . 'We have found that a combination of a low-dose antipsychotic and an antidepressant is helpful for depression, so it makes sense that it will be helpful for PTSD. However, this has been mostly based on clinical decisions, without a heavy research background. Good science is always helpful to support those clinical decisions,' Ritchie told Medscape Medical News . What About Safety? In the phase 3 trial, brexpiprazole plus sertraline had a safety profile consistent with that of brexpiprazole in approved indications. The rate of discontinuation due to adverse events was low (3.9% for brexpiprazole plus sertraline vs 10.2% for sertraline plus placebo), indicating that most participants tolerated the brexpiprazole and sertraline combination treatment, the study team said. In both treatment groups, the only treatment-emergent adverse event (TEAE) with incidence greater than 10% was nausea, a known adverse effect of sertraline treatment. Weight gain was greater in participants receiving the combination. At the last visit, a weight gain of 7% or greater from week 1 was experienced by 8% of participants taking brexpiprazole with the sertraline group and 5% of those taking the sertraline plus placebo. Previous analyses in schizophrenia and MDD show that brexpiprazole is associated with moderate weight gain (+3 to 4 kg over 1 year). The incidence of sedating TEAEs (a concern with some antipsychotics) was generally low, although fatigue (7% vs 4%) and somnolence (5% vs 3%) were more common with brexpiprazole plus sertraline than with sertraline alone. There were no clinically meaningful between-group differences in changes in laboratory test parameters, vital signs, or ECG and participant-reported TEAEs related to suicidality. Potential Concerns As with any new drug application, several questions and issues are likely to be raised by the advisory committee. They could include whether the clinical benefit is substantial enough to warrant approval and how the observed effect sizes compare to existing approved therapies and evidence-based psychotherapies. McIntyre told Medscape Medical News what's particularly noteworthy is that the magnitude of the improvement in PTSD symptoms with brexpiprazole plus sertraline is greater than with sertraline alone. 'That's a very important statement. And this high level of efficacy was consistent on the secondary outcome measures, and the overall tolerability and safety seemed very acceptable,' he said. What's equally important, said McIntyre, is that most people with PTSD have depression and anxiety, and the brexpiprazole plus sertraline combination was more helpful than sertraline alone on the measures of anxiety and depression. 'This is really important, especially in light of the fact that this medication [brexpiprazole] is already approved for adults living with major depressive disorder and inadequate response to antidepressants,' McIntyre said. McIntyre added he suspects some questions the committee may have could relate to the extent to which it's the case that brexpiprazole is effective in PTSD regardless of the antidepressant that is prescribed with it. 'There also will be the inevitable questions about the absence of long-term data which I think will need to be addressed given how chronic and relapse prone this condition is,' McIntyre said. The committee may ask how trauma and PTSD will be screened in primary care and how outcomes related to this therapy will be evaluated in everyday clinical practice, McIntyre said. Overall, McIntyre said brexpiprazole plus sertraline in PTSD is a 'very positive' development for the field. 'PTSD is a terrible condition. It's so darn common, and we just don't have enough treatments for it. The data look good for my perspective. My fingers are crossed for the patients with PTSD and their families,' said McIntyre.
CNN
2 hours ago
- CNN
WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight
Prescription drugs WellnessFacebookTweetLink Follow The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high. The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after the US Food and Drug Administration approved lenacapavir as a twice-yearly injection for the prevention of the human immunodeficiency virus or HIV. Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV. 'These new recommendations are designed for real-world use. WHO is working closely with countries and partners to support the implementation,' Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing. 'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence,' Doherty said. The second recommendation in the guidelines is that rapid diagnostic tests like at-home tests can be used to screen someone for HIV when they are starting, continuing or stopping long-acting medication to prevent infection – called pre-exposure prophylaxis, or PrEP. HIV spreads primarily through unprotected sex or sharing needles. It attacks the body's immune system, and without treatment, it can lead to acquired immunodeficiency syndrome, or AIDS. Globally, about 40 million people were living with HIV at the end of 2023, according to WHO. PrEP has been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting injections, such as every two months of the medication Apretude. But twice-yearly injections of lenacapavir, or LEN, have become another option in the prevention toolbox – not just for the United States but for the world. 'LEN is a six-monthly injectable option, and it may be particularly attractive for people who prefer fewer clinic visits or have challenges with daily oral PrEP. … It could improve adherence and reach more people who need HIV prevention and can be used in pregnant and breastfeeding women,' Doherty said. 'WHO is providing technical assistance to countries interested in adopting LEN and simplified testing strategies, in coordination with global partners like the Global Fund, UNAIDS and several other partners and donors,' she said. 'We call on governments, funders, implementers and civil society to work together for implementing and integrating LEN into the HIV programs. And we believe time to act is now.' There has been growing concern around funding for global HIV prevention efforts. International assistance accounts for 80% of prevention programs in low- and middle-income countries, according to the United Nations. But in the past six months, the United States has significantly withdrawn funding for much of its foreign assistance. The Trump administration has dismantled the US Agency for International Development, or USAID, and reduced funding for the President's Emergency Plan for AIDS Relief, or PEPFAR, which acts as the largest commitment by any nation to address a single disease in history. Gilead Sciences, maker of lenacapavir, announced Wednesday that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir. 'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available,' Gilead Chairman and CEO Daniel O'Day said in a news release. The company added that the cost of lenacapavir under this agreement remains confidential. In the United States, the only place where lenacapavir has received approval for HIV prevention so far, the drug has an annual list price of $28,218 when used for HIV prevention. The cost is similar to the price of other prevention medicine options, according to Gilead. Lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most, Peter Sands, executive director of the Global Fund, said in the news release. 'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required,' he said. 'This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.' The United Nations warned in a report released Thursday that millions more people could die from HIV-related causes by 2029 if funding for HIV programs permanently disappears. Among the 60 low- and middle-income countries included in the report, 25 have indicated increasing their domestic budgets for HIV response efforts next year. But the report noted that may not be sufficient to replace the scale of international funding that these countries have been heavily reliant on. 'We know that PEPFAR had committed $4.3 billion to over 50 countries in 2025, and that support was suddenly ended in January of 2025,' Mary Mahy, director of UNAIDS's Data for Impact department, said in a news briefing. 'If none of the PEPFAR funding is replaced, we'd expect something like 4 million additional deaths between 2025 and 2029, and another 6 million additional new infections,' she said. 'We also know that drug resistance would likely occur with some of those people going off treatment.' Some countries already have seen effects of the rollback of funding for HIV programs, according to Mahy. In Nigeria, facilities reported that there were about 40,000 people who received PrEP at least once during the later part of last year. That number dropped to fewer than 7,000 in April, according to UNAIDS data. A similar trend emerged in Kenya, where there has been a decline in the number of women living with HIV who recently gave birth and received medications to reduce their risk of transmitting the virus to their newborns. About 3,000 women already received medications and nearly 900 initiated medications in October 2024, but those numbers fell to only about 300 already receiving and 100 starting medications in April. 'This is not just a funding gap — it's a ticking time bomb. … We have seen services vanish overnight. Health workers have been sent home. And people — especially children and key populations — are being pushed out of care,' UNAIDS Executive Director Winnie Byanyima said in a news release Thursday. 'There is still time to transform this crisis into an opportunity,' Byanyima said. 'Countries are stepping up with domestic funding. Communities are showing what works. We now need global solidarity to match their courage and resilience,'
